Patients with ER-positive BC being treated with drugs recognised as strong inhibitors or inducers of the isoenzyme CYP3A which cannot be discontinued at least 7 days prior to planned treatment with ribociclib. The gene discussed is CYP3A4; the disease is breast cancer.